LCTX vs. LLY

In the year-to-date period, LCTX achieves a 38.29% return, which is significantly higher than LLY's 9.55% return. Over the past 10 years, LCTX has underperformed LLY with an annualized return of -15.27%, while LLY has yielded a comparatively higher 30.45% annualized return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Lineage Cell Therapeutics, Inc. (LCTX) and Eli Lilly and Company (LLY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current LCTX Sharpe Ratio is -0.37, which is lower than the LLY Sharpe Ratio of 0.47. The chart below compares the historical Sharpe Ratios of LCTX and LLY, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

LCTX has not paid dividends to shareholders, while LLY's dividend yield for the trailing twelve months is around 0.64%.

The maximum LCTX drawdown since its inception was -94.04%, which is greater than LLY's maximum drawdown of -68.27%. Use the drawdown chart below to compare losses from any high point for LCTX and LLY. For additional features, visit the drawdowns tool.

Lineage Cell Therapeutics, Inc. (LCTX) has a higher volatility of 25.84% compared to Eli Lilly and Company (LLY) at 8.93%. This indicates that LCTX's price experiences larger fluctuations and is considered to be riskier than LLY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Lineage Cell Therapeutics, Inc. and Eli Lilly and Company. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.